Dissolving microneedles for transdermal drug delivery in cancer immunotherapy
Source abstract
Abstract
Immunotherapy is an important approach in cancer treatment. Transdermal administration is emerging as a promising method for delivering immunotherapeutics. Dissolving microneedles are made mainly of soluble or biodegradable polymers and have garnered widespread attention due to their painlessness, safety, convenience, excellent drug loading capacity, and easy availability of various materials, making them an ideal transdermal delivery system. This review comprehensively summarized the preparation methods, materials, and applications of dissolving microneedles in cancer vaccines, immune checkpoint inhibitors, and adoptive cell therapy. Additionally, the challenges and perspectives associated with their future clinical translation are discussed.
Source: openalex_inverted_index · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Advancements in Transdermal Drug Delivery · Immunotherapy and Immune Responses · Dermatology and Skin Diseases
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China
Department of Chemistry, University of Washington-Seattle Campus, Seattle, WA, USA
Huahang Microcreate Technology Co., Ltd, Chengdu, China
Funding
Natural Science Foundation of Sichuan Province · National Natural Science Foundation of China · Sichuan University
References (100+)
Show source-provided references
1. Global cancer burden growing, amidst mounting need for services. https://www.who.int/news/item/01-02-2024-global-cancer-burden-growing--amidst-mounting-need-for-services
2. Han · J. Nat. Cancer Center · 2024 · 4 · 4710.1016/j.jncc.2024.01.006 ↗
3. Miller · Ca-Cancer J. Clin. · 2022 · 72 · 40910.3322/caac.21731 ↗
4. Behranvand · Cancer Immunol. Immunother. · 2022 · 71 · 50710.1007/s00262-021-03013-3 ↗
5. Debela · SAGE Open Med. · 2021 · 9 · 2050312121103436610.1177/20503121211034366 ↗
6. Waldman · Nat. Rev. Immunol. · 2020 · 20 · 65110.1038/s41577-020-0306-5 ↗
7. Wang · Cancer Commun. · 2021 · 41 · 80310.1002/cac2.12178 ↗
8. Lin · Nat. Cancer · 2022 · 3 · 91110.1038/s43018-022-00418-6 ↗
9. He · Cell Res. · 2020 · 30 · 66010.1038/s41422-020-0343-4 ↗
10. Kirtane · J. Immunother. Cancer · 2021 · 9 · e00272310.1136/jitc-2021-002723 ↗
11. Rizvi · Science · 2015 · 348 · 12410.1126/science.aaa1348 ↗
12. Chesney · J. Immunother. Cancer · 2022 · 10 · e00575510.1136/jitc-2022-005755 ↗
13. Khattak · Cancer Res. · 2023 · 83 · CT00110.1158/1538-7445.AM2023-CT001 ↗
14. Rojas · Nature · 2023 · 618 · 14410.1038/s41586-023-06063-y ↗
15. Paran · Blood Coagulation Fibrinolysis · 2005 · 16 · 31310.1097/01.mbc.0000172694.85233.a8 ↗
16. Machat · Insights into Imaging · 2019 · 10 · 8610.1186/s13244-019-0770-2 ↗
17. Evans · Vasc. Med. · 2018 · 23 · 41110.1177/1358863X18779695 ↗
18. Prausnitz · Nat. Biotechnol. · 2008 · 26 · 126110.1038/nbt.1504 ↗
19. Li · Acta Pharm. Sin. B · 2019 · 9 · 114510.1016/j.apsb.2019.08.003 ↗
20. Zhang · Research · 2020 · 2020 · 7462915
21. Sheng · Adv. Drug Delivery Rev. · 2021 · 179 · 11391910.1016/j.addr.2021.113919 ↗
22. Gao · Adv. Sci. · 2024 · 11 · 230412410.1002/advs.202304124 ↗
23. Zheng · Nat. Rev. Bioeng. · 202310.1038/s44222-023-00141-6 ↗
24. Li · J. Controlled Release · 2022 · 350 · 93310.1016/j.jconrel.2022.08.022 ↗
25. Ando · Pharmaceutics · 2024 · 16 · 20010.3390/pharmaceutics16020200 ↗
26. Ita · Biomed. Pharmacother. · 2017 · 93 · 111610.1016/j.biopha.2017.07.019 ↗
27. Yu · Nat. Biomed. Eng. · 2020 · 4 · 49910.1038/s41551-019-0508-y ↗
28. Sartawi · J. Controlled Release · 2022 · 348 · 18610.1016/j.jconrel.2022.05.045 ↗
29. Lee · Biomaterials · 2011 · 32 · 313410.1016/j.biomaterials.2011.01.014 ↗
30. Chang · Nat. Biomed. Eng. · 2021 · 5 · 100810.1038/s41551-021-00720-1 ↗
31. McGrath · Eur. J. Pharm. Biopharm. · 2014 · 86 · 20010.1016/j.ejpb.2013.04.023 ↗
32. Kim · J. Controlled Release · 2013 · 170 · 43010.1016/j.jconrel.2013.05.026 ↗
33. Zhang · Adv. Sci. · 2021 · 8 · 210121010.1002/advs.202101210 ↗
34. Yang · Chem. Eng. J. · 2021 · 426 · 13056110.1016/j.cej.2021.130561 ↗
35. Choo · Pharmaceutics · 2022 · 14 · 76610.3390/pharmaceutics14040766 ↗
36. Caudill · Proc. Natl. Acad. Sci. U. S. A. · 2021 · 118 · e210259511810.1073/pnas.2102595118 ↗
37. Detamornrat · Small · 2022 · 18 · 210639210.1002/smll.202106392 ↗
38. Liu · ACS Appl. Mater. Interfaces · 2021 · 13 · 6052210.1021/acsami.1c21489 ↗
39. Li · Int. J. Bioprint. · 2022 · 8 · 55310.18063/ijb.v8i2.553 ↗
40. Li · Mol. Biomed. · 2023 · 4 · 110.1186/s43556-022-00102-2 ↗
41. Chen · Acta Biomater. · 2018 · 65 · 28310.1016/j.actbio.2017.10.030 ↗
42. Liechty · Annu. Rev. Chem. Biomol. Eng. · 2010 · 1 · 14910.1146/annurev-chembioeng-073009-100847 ↗
43. Dabholkar · Int. J. Biol. Macromol. · 2021 · 170 · 60210.1016/j.ijbiomac.2020.12.177 ↗
44. Saha · Carbohydr. Polym. · 2021 · 267 · 11816810.1016/j.carbpol.2021.118168 ↗
45. Abdul Jalal · J. Clin. Med. · 2022 · 11 · 529110.3390/jcm11185291 ↗
46. Jiang · Chin. Chem. Lett. · 2023 · 10868610.1016/j.cclet.2023.108686 ↗
47. Chi · Bioact. Mater. · 2020 · 5 · 253
48. Pineda-Álvarez · J. Pharm. Innov. · 2022 · 17 · 7110.1007/s12247-020-09494-6 ↗
49. Silva · Macromol. Biosci. · 2023 · 23 · 220032310.1002/mabi.202200323 ↗
50. Tian · J. Pharm. Sci. · 2022 · 111 · 107010.1016/j.xphs.2022.01.033 ↗
51. Wang · Adv. Mater. · 2022 · 34 · 210660610.1002/adma.202106606 ↗
52. Zhu · Small · 2020 · 16 · 190591010.1002/smll.201905910 ↗
53. Lv · Adv. Healthcare Mater. · 2023 · 12 · 220329510.1002/adhm.202203295 ↗
54. Ramadon · Pharmaceutics · 2023 · 15 · 28910.3390/pharmaceutics15010289 ↗
55. Sabbagh · Polymers · 2023 · 15 · 203110.3390/polym15092031 ↗
56. Li · Nat. Sci. Rev. · 2022 · 9 · nwab17210.1093/nsr/nwab172 ↗
57. Wang · Chem. Eng. J. · 2022 · 428 · 13191310.1016/j.cej.2021.131913 ↗
58. Chen · ACS Nano · 2016 · 10 · 9310.1021/acsnano.5b05043 ↗
59. Zheng · NPG Asia Mater. · 2024 · 16 · 110.1038/s41427-024-00531-1 ↗
60. Chang · Bioeng. Trans. Med. · 2022 · e10457
61. Liu · J. Hematol. Oncol. · 2022 · 15 · 2810.1186/s13045-022-01247-x ↗
62. Carmona-Cruz · Vacres · 2020 · 7 · 1510.52547/vacres.7.2.15 ↗
63. Honda · Int. Immunol. · 2019 · 31 · 42310.1093/intimm/dxz005 ↗
64. Menon · Micromachines · 2021 · 12 · 43510.3390/mi12040435 ↗
65. Xu · J. Controlled Release · 2022 · 351 · 90710.1016/j.jconrel.2022.10.008 ↗
66. Chen · Chin. Chem. Lett. · 2023 · 10870610.1016/j.cclet.2023.108706 ↗
67. Kulkarni · Nat. Nanotechnol. · 2021 · 16 · 63010.1038/s41565-021-00898-0 ↗
68. Mendes · Nat. Rev. Methods Primers · 2022 · 2 · 110.1038/s43586-022-00104-y ↗
69. Gupta · Adv. Drug Delivery Rev. · 2021 · 178 · 11383410.1016/j.addr.2021.113834 ↗
70. Ali · Nanomed. Nanotechnol. Biol. Med. · 2017 · 13 · 92110.1016/j.nano.2016.11.019 ↗
71. Cole · Acta Biomater. · 2019 · 96 · 48010.1016/j.actbio.2019.07.003 ↗
72. Yang · J. Controlled Release · 2023 · 357 · 64110.1016/j.jconrel.2023.04.031 ↗
73. Balmert · J. Controlled Release · 2020 · 317 · 33610.1016/j.jconrel.2019.11.023 ↗
74. Guo · Appl. Mater. Today · 2021 · 24 · 10111010.1016/j.apmt.2021.101110 ↗
75. Boone · ACS Appl. Nano Mater. · 2020 · 3 · 803710.1021/acsanm.0c01506 ↗
76. M.Zaric , et al. , Skin Dendritic Cell Targeting via Microneedle Arrays Laden with Antigen-Encapsulated Poly-d,l-lactide-co-Glycolide Nanoparticles Induces Efficient Antitumor and Antiviral Immune Responses , ACS Publications , 2013 10.1021/nn304235j , https://pubs.acs.org/doi/full/10.1021/nn304235j10.1021/nn304235j ↗
77. Singh · Cancer Immunol. Immunother. · 2019 · 68 · 84910.1007/s00262-018-2276-z ↗
78. Guo · J. Immunother. Cancer · 2019 · 7 · 610.1186/s40425-018-0495-7 ↗
79. bin Umair · Arch. Virol. · 2022 · 167 · 138710.1007/s00705-022-05432-8 ↗
80. Ruzzi · Int. J. Mol. Sci. · 2023 · 24 · 1296310.3390/ijms241612963 ↗
81. Hills · Curr. Opin. Biotechnol · 2022 · 73 · 34610.1016/j.copbio.2021.09.012 ↗
82. Tornesello · Vaccines · 2022 · 10 · 22710.3390/vaccines10020227 ↗
83. Carlino · Lancet · 2021 · 398 · 100210.1016/S0140-6736(21)01206-X ↗
84. Yi · Mol. Cancer · 2022 · 21 · 2810.1186/s12943-021-01489-2 ↗
85. Adams · JAMA Oncol. · 2019 · 5 · 120510.1001/jamaoncol.2018.7147 ↗
86. Huang · JCO · 2023 · 41 · 303210.1200/JCO.22.02367 ↗
87. Wang · Nano Lett. · 2016 · 16 · 233410.1021/acs.nanolett.5b05030 ↗
88. Ye · ACS Nano · 2016 · 10 · 895610.1021/acsnano.6b04989 ↗
89. Lopez-Ramirez · Adv. Mater. · 2020 · 32 · 190574010.1002/adma.201905740 ↗
90. Mallakpour · Int. J. Biol. Macromol. · 2021 · 182 · 193110.1016/j.ijbiomac.2021.05.155 ↗
91. Yin · Mater. Horiz. · 202410.1039/D3MH02251J ↗
92. Ukawa · Mol. Pharmaceutics · 2019 · 16 · 110510.1021/acs.molpharmaceut.8b01110 ↗
93. Conte · J. Funct. Biomater. · 2023 · 14 · 8210.3390/jfb14020082 ↗
94. Dmour · Int. J. Biol. Macromol. · 2022 · 200 · 49810.1016/j.ijbiomac.2021.12.129 ↗
95. Gong · Vaccines · 2022 · 10 · 190610.3390/vaccines10111906 ↗
96. Taylor · J. Biol. Chem. · 2007 · 282 · 1826510.1074/jbc.M606352200 ↗
97. Powell · Immunol. Res. · 2005 · 31 · 20710.1385/IR:31:3:207 ↗
98. Gilardi · Mol. Cancer Ther. · 2022 · 21 · 61610.1158/1535-7163.MCT-21-0234 ↗
99. Joo · Adv. Mater. · 2023 · 35 · 220996610.1002/adma.202209966 ↗
100. Chan · Nat. Rev. Immunol. · 2021 · 21 · 76910.1038/s41577-021-00539-6 ↗